Regenerative Medicine Moves into the Spotlight
February 1, 2019
The regenerative medicine sector won major product approvals, advanced a growing pipeline of therapies in development, and enjoyed a surge of investment in 2018. As excitement grows about the potential of these therapies, the industry is also wrestling with complex policy issues that could determine how sustainable these businesses will be and whether patients will ever get to benefit from the potential cures that may soon be within reach. We spoke to Matt Patterson, chairman of the Alliance for Regenerative Medicine, about the state of the industry, ongoing debates about pricing and payment models, and what the industry will need to do to educate patients and policymakers about this emerging area of medicine.
Sign up for updates straight to your inbox.